EVX-01

Phase 2Small molecule

EEvaxion Biotech A/S

EVX-01 is one of 46 small molecule programs targeting Metastatic Melanoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic MelanomaActive, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Metastatic Melanoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Approved

31 2

Keytruda

Merck & Co.

Phase 3

39 3

Yervoy

Bristol-Myers Squibb

Phase 3

43 4

Fludara

Sanofi

Phase 3

21 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

44 6

Rifadin

Imbruvica

2 8

Mektovi

Pfizer

Phase 3

6 9

Braftovi

Pfizer

Phase 3

5 10

Farydak

SSecuraBio

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic Melanoma1 trial

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Active, not recruiting·EEvaxion Biotech A/S·Phase 2·NCT05309421·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EVX-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EVX-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EVX-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Evaxion Biotech A/S company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEvaxion Biotech A/S

EVX-01

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic Melanoma1 trial

References

Drug Info

Quick Facts

Related News